Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's Why
01:33pm, Wednesday, 21'st Sep 2022
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 106% to Reach the Level Wall Street Analysts Expect?
01:55pm, Monday, 22'nd Aug 2022 Zacks Investment Research
The consensus price target hints at a 106% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend
Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 106% to Reach the Level Wall Street Analysts Expect?
11:17am, Monday, 22'nd Aug 2022
The consensus price target hints at a 106% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend
Kiniksa Pharmaceuticals, Ltd. (KNSA) CEO Sanj Patel on Q2 2022 Results - Earnings Call Transcript
03:45pm, Friday, 05'th Aug 2022
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Offi
Wall Street Analysts See an 114% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?
01:55pm, Friday, 05'th Aug 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 113.9% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is q
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates
12:45pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the s
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
11:30am, Wednesday, 03'rd Aug 2022 GlobeNewswire Inc.
– ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 –
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
11:29am, Wednesday, 03'rd Aug 2022 GlobeNewswire Inc.
– Kiniksa to receive $100 million in upfront and near-term payments –
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates
09:47am, Wednesday, 03'rd Aug 2022
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's What You Should Know
04:00pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's What You Should Know
02:04pm, Friday, 22'nd Jul 2022
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Cytokinetics (CYTK) Soars 6.1%: Is Further Upside Left in the Stock?
01:14pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term
Kiniksa Pharmaceuticals (KNSA) CEO Sanj Patel on Q1 2022 Results - Earnings Call Transcript
04:12pm, Saturday, 07'th May 2022
Kiniksa Pharmaceuticals (NASDAQ:KNSA ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Rachel Frank - Head of IR Sanj Patel - CEO and Chairman Ross Moat - Chief Commercial
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
01:15pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.77% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
10:32am, Tuesday, 03'rd May 2022
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.77% and 0.83%, respectively, for the quarter ended March 2022.
